Sierra Sees Momelotinib ‘Sweet Spot’ In Anemic Myelofibrosis Population
Executive Summary
Sierra announced Phase III results for the JAK inhibitor in anemic myelofibrosis patients with previous JAK exposure, a difficult-to-treat population. Trial investigator Ruben Mesa talked to Scrip about some of the advantages.